Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

HCRN Endoscopische versus shuntbehandeling van hydrocephalus bij zuigelingen (ESTHI)

22 september 2026 bijgewerkt door: John Kestle, University of Utah

Endoscopische versus shuntbehandeling van hydrocephalus bij zuigelingen

Hydrocephalus is a potentially debilitating neurological condition that primarily affects babies under a year of age and has traditionally been treated by inserting a shunt between the brain and the abdomen. A newer endoscopic procedure offers hope of shunt- free treatment that may reduce complications over a child's life, but it is not clear if the endoscopic procedure results in similar intellectual outcome as shunt. Therefore, the investigators propose a randomized trial to compare intellectual outcome and brain structural integrity between these two treatments, to help families make the best treatment decision for their baby.

Studie Overzicht

Gedetailleerde beschrijving

The ESTHI Trial is a multi-center randomized controlled trial (RCT) comparing endoscopic third ventriculostomy with choroid plexus cauterization (ETV+CPC) and shunt in infants with hydrocephalus. The study will leverage the infrastructure of the Hydrocephalus Clinical Research Network (HCRN), a committed group of 14 leading North American pediatric neurosurgical centers with a long track-record of successful collaborative clinical research and RCTs in hydrocephalus. Optimal cognitive outcome is the primary concern of families and will, therefore, be the primary outcome. Assessment of dMRI, a validated, non-invasive method of measuring white matter microstructural integrity and structural connectivity in the developing brain, will provide further insight into the developmental consequences of these two treatments. The results of the RCT will help families determine the optimal treatment of hydrocephalus for their child.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

165

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Alberta
      • Calgary, Alberta, Canada, T3B 6A8
        • Alberta Children's Hospital
    • British Columbia
      • Vancouver, British Columbia, Canada, V6H 3V4
        • British Columbia Children's Hospital
    • Ontario
      • Toronto, Ontario, Canada, M5G 1X8
        • The Hospital for Sick Children
    • Alabama
      • Birmingham, Alabama, Verenigde Staten, 35233
        • Children's of Alabama
    • Arizona
      • Phoenix, Arizona, Verenigde Staten, 85016
        • Phoenix Children's Hospital
    • California
      • Los Angeles, California, Verenigde Staten, 90027
        • Children's Hospital of Los Angeles
    • Colorado
      • Aurora, Colorado, Verenigde Staten, 80045
        • Children's Hospital Colorado
    • Connecticut
      • New Haven, Connecticut, Verenigde Staten, 06520
        • Yale University
    • Florida
      • Jacksonville, Florida, Verenigde Staten, 32207
        • Wolfson Children's Hospital
      • Orlando, Florida, Verenigde Staten, 32806
        • Arnold Palmer Hospital for Children
    • Indiana
      • Indianapolis, Indiana, Verenigde Staten, 46202
        • Trustees of Indiana University
    • Maryland
      • Baltimore, Maryland, Verenigde Staten, 21287
        • Johns Hopkins Children's Center
    • Missouri
      • St Louis, Missouri, Verenigde Staten, 63110
        • St. Louis Children's Hospital
    • Ohio
      • Columbus, Ohio, Verenigde Staten, 43205
        • Nationwide Children's Hospital
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15224
        • Children's Hospital of Pittsburgh of UPMC
      • University Park, Pennsylvania, Verenigde Staten, 16802
        • The Pennsylvania State University
    • Tennessee
      • Nashville, Tennessee, Verenigde Staten, 37232
        • Monroe Carell Jr. Children's Hospital at Vanderbilt
    • Texas
      • Houston, Texas, Verenigde Staten, 77030
        • Texas Children's Hospital
    • Utah
      • Salt Lake City, Utah, Verenigde Staten, 84118
        • Primary Children's Hospital
    • Virginia
      • Richmond, Virginia, Verenigde Staten, 23284
        • Virginia Commonwealth University
    • Washington
      • Seattle, Washington, Verenigde Staten, 98105
        • Seattle Children's Hospital

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

1 dag tot 1 jaar (Kind)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Corrected age <104 weeks and 0 days,

    AND

  2. Child is ≥ 37 weeks post menstrual age,

    AND

  3. Child must have symptomatic hydrocephalus, defined as:

    Ventriculomegaly on MRI (frontal-occipital horn ratio (FOR) >0.45, which approximates "moderate ventriculomegaly"), and at least one of the following:

    • Head circumference >98th percentile for corrected age with either bulging fontanelle or splayed sutures
    • Upgaze paresis/palsy (sundowning)
    • CSF leak
    • Papilledema
    • Tense pseudomeningocele or tense fluid along a track
    • Vomiting or irritability, with no other attributable cause
    • Bradycardias or apneas, with no other attributable cause
    • Intracranial pressure (ICP) monitoring showing persistent elevation of pressure with or without plateau waves

    AND

  4. No prior history of shunt insertion or endoscopic third ventriculostomy (ETV) procedure (previous temporization devices and/or external ventricular drains permissible)

Exclusion Criteria:

  1. Hydrocephalus due to intraventricular hemorrhage in a child born before 37 weeks gestational age; OR

  2. Anatomy not suitable for ETV+CPC or anteriorly placed ventriculoperitoneal shunt defined as:

    • Moderate to severe prepontine adhesions on steady state free precession (SSFP) or T2 weighted fast (turbo) spin echo (FSE/TSE) MRI, which includes the following sequences: FIESTA, FIESTA-C, TrueFISP, CISS, Balanced FFE (bFFE), CUBE, SPACE, VISTA, IsoFSE, and 3D MVOX
    • Closure of one or both foramina of Monro
    • Thick floor of third ventricle (≥ 3mm)
    • Narrow third ventricle (<5mm)
    • Presence of scalp, bone, or ventricular lesions that make placement of an anterior shunt impracticable; OR
  3. Underlying condition with a high chance of mortality within 12 months; OR

  4. Hydrocephalus with loculated CSF compartments; OR

  5. Peritoneal cavity not suitable for distal shunt placement; OR

  6. Active CSF infection; OR

  7. Hydranencephaly; OR

  8. Child requires an intraventricular procedure (e.g. endoscopic biopsy) in addition to the initial first-time permanent procedure for the treatment of hydrocephalus.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: ETV+CPC

Subjects randomized to this arm will undergo an ETV+CPC procedure for treatment of Hydrocephalus

Since the early 1990s, ETV has become the main alternative to shunting for hydrocephalus. This procedure involves placing an endoscopic camera into the ventricles of the brain and creating a hole in the floor of the third ventricle to act as an internal bypass for obstructed CSF. The cauterization of choroid plexus (CPC) involves the use of a device to burn or cauterize tissue from the choroid plexus. The choroid plexus of the brain exists in the lateral ventricles, the third ventricle, and the fourth ventricle. Its main role is the production of CSF. The success of ETV alone is poor in infants, but when combined with CPC, improved results have been observed and ETV+CPC has become a safe viable option for these children.

Actieve vergelijker: Ventriculoperitoneal Shunt

Subjects randomized to this arm will undergo a Ventriculoperitoneal Shunt procedure for treatment of Hydrocephalus

The most common treatment for hydrocephalus has been the insertion of a ventriculoperitoneal shunt, which has been in popular use for over 50 years. This consists of silastic tubing attached to a valve mechanism that runs subcutaneously from the head to the abdomen. It is one of the most common procedures performed by pediatric neurosurgeons.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Bayley Scale of Infant Development-IV (Bayley-IV) Cognitive Scale score
Tijdsspanne: 12 months post randomized surgical intervention

The primary objective is to determine, in infants <104 weeks corrected age, with hydrocephalus requiring treatment at tertiary care pediatric neurosurgery centers in North America, if treatment with ETV+CPC compared to shunt results in non-inferior cognitive outcome at 12 months from surgery, as measured by Bayley-IV Cognitive Scale score with a non-inferiority margin of 1.5. Scaled scores range from 1-19. Higher scores indicate better outcomes. Scores will also be obtained at 3 and 5 years of age.

12 months post randomized surgical intervention

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Bayley Scale of Infant Development-IV (Bayley-IV) Language Scaled Score
Tijdsspanne: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Bayley-IV Language Scaled scores. Scaled scores range from 1-19. Higher scores indicate better outcomes.

12 months post randomized surgical intervention
Bayley Scale of Infant Development-IV (Bayley-IV) Motor Scaled Score
Tijdsspanne: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Bayley-IV Motor Scaled scores. Scaled scores range from 1-19. Higher scores indicate better outcomes.

12 months post randomized surgical intervention

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Vineland-3 Communication Domain Score
Tijdsspanne: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Vineland-3 Communication Domain scores. Domain scores range from 20-140. Higher scores indicate better outcomes.

12 months post randomized surgical intervention
Vineland-3 Daily Living Skills Domain Score
Tijdsspanne: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Vineland-3 Daily Living Skills Domain scores. Domain scores range from 20-140. Higher scores indicate better outcomes.

12 months post randomized surgical intervention
Vineland-3 Socialization Domain Score
Tijdsspanne: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Vineland-3 Socialization Domain scores. Domain scores range from 20-140. Higher scores indicate better outcomes.

12 months post randomized surgical intervention
Vineland-3 Motor Skills Domain Score
Tijdsspanne: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Vineland-3 Motor Skills Domain scores. Domain scores range from 20-140. Higher scores indicate better outcomes.

12 months post randomized surgical intervention
Vineland-3 Adaptive Behavior Composite Score
Tijdsspanne: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Vineland-3 Adaptive Behavior Composite (ABC) scores. ABC scores range from 20-140. Higher scores indicate better outcomes.

12 months post randomized surgical intervention
The occurrence of treatment failure.
Tijdsspanne: Through study completion, a maximum of 7 years.

Treatment failure is defined as obstruction, loculated compartments, overdrainage, CSF infection, or significant intraoperative complication. The rate of occurrence of each type, for the initial procedure, will be calculated. Failure can be captured at anytime during the course of the 7 year study. Occurrence between treatment arms will be compared.

Through study completion, a maximum of 7 years.
Time to failure.
Tijdsspanne: Through study completion, a maximum of 7 years

Time to failure is the number of days in which the intervention is functionally successful. It is calculated from date of surgery to date of failure, as described in Outcome 9. Time to failure between treatment arms will be compared.

Through study completion, a maximum of 7 years
Total number of hospital admission days within 12 months after surgery
Tijdsspanne: 12 months post randomized surgical intervention

Number of days subject is admitted to the hospital during the first 12 months following the initial surgical intervention. All hospital admissions included, regardless of reason for admission. Number of hospital admission days between treatment arms will be compared.

12 months post randomized surgical intervention
Total number of repeat surgeries within 12 months after surgery
Tijdsspanne: 12 months post randomized surgical intervention

Number of shunt and ETV+CPC procedures during the first 12 months following the initial surgical intervention. Number of repeat surgeries between treatment arms will be compared.

12 months post randomized surgical intervention
Total number of brain imaging (CT, MRI, ultrasound) scans within 12 months after surgery
Tijdsspanne: 12 months post randomized surgical intervention

Number of CT, MRI, and ultrasound brain scans during the first 12 months following the initial surgical intervention. Total imaging between treatment arms will be compared.

12 months post randomized surgical intervention
All major peri-operative and post-operative complications
Tijdsspanne: Through study completion, a maximum of 7 years

Number of peri-operative and post-operative complications to include those related to CSF circulation, infection, hemorrhage, seizures, and new neurological deficits. Number of complications between treatment arms will be compared.

Through study completion, a maximum of 7 years
Brain and ventricle volume on MRI performed at 12 months after surgery
Tijdsspanne: 12 months post randomized surgical intervention

Brain and CSF volumes will be converted to Z-scores based on previously described age- and sex-adjusted distributions and used for comparison of brain volume and growth between ETV+CPC and shunt treatment groups.

12 months post randomized surgical intervention
dMRI corpus collosum (CC) and corticospinal tract (CST) fractional anisotropy (FA) at 12 months after surgery.
Tijdsspanne: 12 months post randomized surgical intervention

Develop dMRI maps, including fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD). Tract-based spatial statistics (TBSS) will be used for voxel-wise analyses of white matter tracts. Maps will be used to compare cerebral structural connectivity between the two treatment arms.

12 months post randomized surgical intervention
Cerebral spinal fluid myelin basic protein (MBP) levels measured at the time of ETV+CPC or shunt
Tijdsspanne: 12 months post randomized surgical intervention

Examine correlations of cerebral spinal fluid myelin basic protein (MBP) levels to post-operative Bayley-IV Cognitive Scale score.

12 months post randomized surgical intervention
Cerebral spinal fluid amyloid precursor protein (APP) levels measured at the time of ETV+CPC or shunt
Tijdsspanne: 12 months post randomized surgical intervention

Examine correlations of cerebral spinal fluid amyloid precursor protein (APP) to post-operative Bayley-IV Cognitive Scale score

12 months post randomized surgical intervention
Cerebral spinal fluid NCAM-1 levels measured at the time of ETV+CPC or shunt
Tijdsspanne: 12 months post randomized surgical intervention

Examine correlations of cerebral spinal fluid NCAM-1 levels to post-operative Bayley-IV Cognitive Scale score

12 months post randomized surgical intervention
Cerebral spinal fluid glial fibrillary acid protein (GFAP) levels measured at the time of ETV+CPC or shunt
Tijdsspanne: 12 months post randomized surgical intervention

Examine correlations of cerebral spinal fluid glial fibrillary acid protein (GFAP) to post-operative Bayley-IV Cognitive Scale score

12 months post randomized surgical intervention
Wechsler Preschool & Primary Scale of Intelligence (WPPSI) Scores
Tijdsspanne: At 5 years of age

To determine, in infants who reach 5 years of age before the end of the study, if ETV+CPC compared to shunt results in non-inferior WPPSI scaled scores. Scaled scores range from 1-19. Higher scores indicate better outcomes.

At 5 years of age
Health related quality of life (HRQoL) measurements
Tijdsspanne: 12 months post randomized surgical intervention, and at 3 and 5 years of age

To compare health-related quality of life (HRQoL), as measured by vi-sual analogue scales (VAS), Health Utilities Preschool (HuPS), and the Hydrocephalus Outcome Questionnaire (HOQ), between treatment arms.

12 months post randomized surgical intervention, and at 3 and 5 years of age

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

21 juli 2020

Primaire voltooiing (Geschat)

30 mei 2027

Studie voltooiing (Geschat)

31 augustus 2027

Studieregistratiedata

Eerst ingediend

27 oktober 2019

Eerst ingediend dat voldeed aan de QC-criteria

22 november 2019

Eerst geplaatst (Werkelijk)

26 november 2019

Updates van studierecords

Laatste update geplaatst (Werkelijk)

25 september 2026

Laatste update ingediend die voldeed aan QC-criteria

22 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

After subject enrollment and 5 year follow up have been completed, we will prepare a final study database for analysis. A releasable database will be produced and completely de-identified in accordance with the definitions provided in the Health insurance Portability and Accountability Act (HIPAA). Namely, all identifiers specified in HIPAA will be recoded in a manner that will make it impossible to deduce or impute the specific identity of any patient. The database will not contain any institutional identifiers. We will also prepare a data dictionary that provides a concise definition of every data element included in the database. If specific data elements have idiosyncrasies that might affect interpretation or analysis, this will be discussed in the dictionary document.

In accordance with policies determined by the investigators and funding sponsors, the releasable database will be provided to users in electronic form.

IPD-tijdsbestek voor delen

Within one year of primary publication or within 18 months of the last study visit of the last subject, whichever occurs first.

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren